A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

Summary

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive). Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

Timeline

Start

2025-08-08

Primary completion

2027-05

Completion

2027-08

Drugs

Indications